A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)

Trial Profile

A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Ruxolitinib (Primary) ; Capecitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms JANUS 2
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 06 Mar 2018 Primary endpoint (Overall Survival (OS)) has not been met as per the results published in the Investigational New Drugs
    • 06 Mar 2018 Results assessing safety and efficacy published in the Investigational New Drugs
    • 12 May 2017 This trial has been completed in Sweden.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top